James M. Kohosek - May 24, 2023 Form 4 Insider Report for Evoqua Water Technologies Corp. (AQUA)

Role
EVP, Chief Admin. Officer
Signature
/s/ John DiMascio, Attorney-in-Fact for James M. Kohosek
Stock symbol
AQUA
Transactions as of
May 24, 2023
Transactions value $
$0
Form type
4
Date filed
5/26/2023, 04:33 PM
Previous filing
May 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AQUA Common Stock Award $0 +17.2K +18.72% $0.00 109K May 24, 2023 Direct F1
transaction AQUA Common Stock Disposed to Issuer -109K -100% 0 May 24, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AQUA Stock Option (Right to Buy) Disposed to Issuer -26.5K -100% 0 May 24, 2023 Common Stock 26.5K $20.88 Direct F3, F4, F5
transaction AQUA Stock Option (Right to Buy) Disposed to Issuer -32.5K -100% 0 May 24, 2023 Common Stock 32.5K $12.67 Direct F3, F4, F5
transaction AQUA Stock Option (Right to Buy) Disposed to Issuer -24.8K -100% 0 May 24, 2023 Common Stock 24.8K $23.63 Direct F4, F5, F6
transaction AQUA Stock Option (Right to Buy) Disposed to Issuer -19.5K -100% 0 May 24, 2023 Common Stock 19.5K $24.76 Direct F4, F5, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

James M. Kohosek is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents performance share units ("PSUs") that became earned (at target award level) pursuant to the merger agreement among Xylem Inc., Fore Merger Sub, Inc. and the issuer, dated as of Jan. 22, 2023, upon effectiveness of the merger on May 24, 2023.
F2 Disposed of pursuant to the merger agreement. Upon effectiveness of the merger, (i) each issued and outstanding share of issuer common stock was exchanged for 0.48 Xylem common shares, with cash paid in lieu of fractional shares, and (ii) unvested restricted stock units ("RSUs") and PSUs (at target award level) were converted into RSUs relating to Xylem common shares, by multiplying the number of shares of issuer common stock underlying the award and 0.48, rounded down to the nearest whole share.
F3 This option is fully vested.
F4 Pursuant to the merger agreement, outstanding options for issuer common stock were assumed by Xylem and converted into options for Xylem common shares, in an amount equal to the number of shares of issuer common stock underlying the options multiplied by 0.48, rounded down to the nearest whole share.
F5 Pursuant to the merger agreement, the Xylem option exercise price is equal to the issuer option exercise price divided by 0.48, rounded up to the nearest whole cent.
F6 This option vests in four equal annual installments starting on Jan. 1, 2021.
F7 This option vests in four equal annual installments starting on Feb. 16, 2022.